Ribociclib is already approved by the Food and Drug Administration as an initial, or first line, treatment with an aromatase inhibitor, like letrozole for postmenopausal women with HR positive, HER2 negative advanced breast cancer <a href=https://lasix.mom>lasix in usa</a>